383 related articles for article (PubMed ID: 28858267)
1. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.
Keely NO; Carr M; Yassin B; Ana G; Lloyd DG; Zisterer D; Meegan MJ
Biomedicines; 2016 Jul; 4(3):. PubMed ID: 28536383
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
[TBL] [Abstract][Full Text] [Related]
4. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
6. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
7. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer.
Seo JW; Comninos JS; Chi DY; Kim DW; Carlson KE; Katzenellenbogen JA
J Med Chem; 2006 Apr; 49(8):2496-511. PubMed ID: 16610793
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents.
Zhu H; Huang L; Zhang Y; Xu X; Sun Y; Shen YM
J Biol Inorg Chem; 2010 May; 15(4):591-9. PubMed ID: 20195693
[TBL] [Abstract][Full Text] [Related]
9. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
13. Discovery and hit to lead optimization of novel combretastatin A-4 analogues: dependence of C-linker length and hybridization.
Provot O; Hamze A; Peyrat JF; Brion JD; Alami M
Anticancer Agents Med Chem; 2013 Dec; 13(10):1614-35. PubMed ID: 24261611
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of arylcinnamide linked combretastatin-A4 hybrids as tubulin polymerization inhibitors and apoptosis inducing agents.
Kamal A; Bajee S; Lakshma Nayak V; Venkata Subba Rao A; Nagaraju B; Ratna Reddy C; Jeevak Sopanrao K; Alarifi A
Bioorg Med Chem Lett; 2016 Jun; 26(12):2957-2964. PubMed ID: 27161282
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates.
O'Boyle NM; Ana G; Kelly PM; Nathwani SM; Noorani S; Fayne D; Bright SA; Twamley B; Zisterer DM; Meegan MJ
Org Biomol Chem; 2019 Jun; 17(25):6184-6200. PubMed ID: 31173031
[TBL] [Abstract][Full Text] [Related]
17. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro cytotoxicity evaluation of β-carboline-combretastatin carboxamides as apoptosis inducing agents: DNA intercalation and topoisomerase-II inhibition.
Jadala C; Sathish M; Reddy TS; Reddy VG; Tokala R; Bhargava SK; Shankaraiah N; Nagesh N; Kamal A
Bioorg Med Chem; 2019 Aug; 27(15):3285-3298. PubMed ID: 31227365
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
